Drug of Abuse, Barbiturate Screen with GC-MS Confirmation, Urine
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Screening and confirming drug abuse involving barbiturates such as amobarbital, butalbital, pentobarbital, phenobarbital, and secobarbital.
Reflex Tests Lists test(s) that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial test(s)
|Test ID||Reporting Name||Available Separately||Always Performed|
|MSBR||Drug of Abuse, Barbiturate Conf, U||Yes||No|
Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
If the barbituate screen is > or =200 ng/mL then barbiturate confirmation is performed at an additional charge.
DABAR/505335: Enzyme-Multiplied Immunoassay Technique (EMIT)
MSBR/500367: Gas Chromatography-Mass Spectrometry (GC-MS)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Drug of Abuse, Barbiturate, U
Specimen Type Describes the specimen type needed for testing
Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Container/Tube: Plastic, 10-mL urine tube (Supply T068)
Specimen Volume: 10 mL
1. Collect a random urine specimen.
2. No preservative.
Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.
Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
|Urine||Refrigerated (preferred)||14 days|
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Barbiturates constitute a class of central nervous system depressants. They are classified on their duration of action. The duration of action is approximately 15 minutes for the short-acting types (eg, secobarbital and pentobarbital), and a day or more for the long-acting types (eg, phenobarbital). Short-acting barbiturates are usually excreted in the urine as metabolites, while the long-acting barbiturates appear primarily unchanged.
Barbiturates were originally introduced as sleep inducers. Butalbital also is used to control severe headaches. Mephobarbital and phenobarbital are frequently used to control major motor (grand mal) seizures.
These drugs are commonly abused as "downers" to induce sleep after an amphetamine- or cocaine-induced "high".
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Positives are reported with a quantitative GC-MS result.
EMIT cutoff concentration: 200 ng/mL
The presence of barbiturate in urine at >300 ng/mL indicates use of one of these drugs. Most barbiturates are fast acting; their presence indicates use within the past 3 days. Phenobarbital, commonly used to control epilepsy, has a very long half-life. The presence of phenobarbital in urine indicates that the patient has used the drug sometime within the past 30 days.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
No significant cautionary statements. This test is very specific for these compounds.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
Baselt RC, Cravey RH: Disposition of Toxic Drugs and Chemicals In Man. 3rd edition. Chicago, IL Year Book Medical Publishers, 1989
Method Description Describes how the test is performed and provides a method-specific reference
Urine is preliminarily screened for the presence of barbiturates by immunoassay technique. If the result is positive by this technique, the urine is subjected to gas chromatography/mass spectrometry analysis. If a compound chromatographs where a barbiturate standard emerges with a mass spectrum consistent with that of a specific barbiturate drug, the presence of that barbiturate drug is confirmed. (Schwarzhoff RH, Hubster EC, Liserio MK: Enzyme immunoassay, kinetic microparticle immunoassay, radioimmunoassay, and fluorescence polarization immunoassay compared for drug-of-abuse screening. Clin Chem 39:2137-2146, 1993; Foerster EH, Dempse J, Garriott JC: A gas chromatographic screening procedure for acid and neutral drugs in blood. J Anal Toxicol 3:87-91, 1979)
Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Screening performed Monday through Friday, Sunday
Gas Chromatography-Mass Spectrometry (GC-MS) confirmation performed twice a week
Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location The location of the laboratory that performs the test
Test Classification Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.
This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
G0431-Screen–government payers (if appropriate)
82205-Confirmation (if appropriate)
LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
|Result ID||Reporting Name||LOINC Code|